OncoSec Medical Inc. plans to sell its common shares in an underwritten public offering.
The company plans to grant the underwriters an option to buy up to an additional 15% of the shares offered.
OncoSec plans to use the net proceeds primarily for a phase 2 trial in skin cancer, for other clinical and research and development activities, and for working capital and general corporate purposes.
Piper Jaffray & Co. is acting as lead book-running manager for the offering. Cantor Fitzgerald & Co. is also acting as a book runner.
